Pfizer is trading like it caught a cold, despite showing strong financial health post-COVID. In Q4 2024, Pfizer raked in ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Fox News contributor Dr. Marty Makary cleared the final hurdle to a final confirmation vote on Tuesday, inching closer to ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

President Donald Trump’s tariffs on pharmaceuticals "to come at some point" as companies promise to build infrastructure in ...

The PMCPA has dug into the industry’s LinkedIn activities once again. | The PMCPA has dug into the industry’s LinkedIn ...

This article explains why investors should brace for big changes on April 1 when it will go through a reconstitution.

Equities research analysts at Zacks Research reduced their Q2 2026 earnings per share (EPS) estimates for Pfizer in a report issued on Thursday, March 20th. Zacks Research analyst K. Shah now ...

The Mayo Clinic and Xact Sciences are developing an easy, noninvasive test to detect endometrial cancer in women with ...

Pfizer, Merck & Co., Inc., UnitedHealth Group, Eli Lilly and Company, and AbbVie are the five Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks are shares in ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...